CrossrefInfokarte
Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study
Breast Cancer · 2026-11-10
DOI: 10.1007/s12282-026-01931-7 ↗Abstract
Kein Abstract verfügbar.
EUVIMED